Comparative Pharmacology
Head-to-head clinical analysis: AVZIVI versus PYZCHIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVZIVI versus PYZCHIVA.
AVZIVI vs PYZCHIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avizivi (avelumab) is a human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors. This restores anti-tumor immune responses, including T-cell activation and proliferation, by reversing PD-L1-mediated inhibition.
Biosimilar to infliximab; a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), neutralizing its activity and reducing inflammation.
IV 200 mg over 30 minutes on Day 1 of a 21-day cycle, in combination with paclitaxel and carboplatin; continue until disease progression or unacceptable toxicity.
Intravenous infusion of 300 mg over 60 minutes on days 1, 15, and 29, then every 4 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; prolonged to 24–48 h in moderate-to-severe renal impairment.
Terminal elimination half-life approximately 21-25 days (mean 23 days), consistent with IgG1 monoclonal antibody clearance; supports monthly dosing.
Primarily renal excretion as unchanged drug (~70%) and glucuronide conjugate (~30%); biliary/fecal excretion accounts for <5%.
Primarily eliminated via the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor